Metabolic and electrolyte abnormalities as risk factors in drug-induced long QT syndrome

Clifford TeBay1 · Adam P. Hill1,2 · Monique J. Windley1,2

Received: 10 December 2021 / Accepted: 4 January 2022 / Published online: 27 January 2022
© The Author(s) 2022

Abstract
Drug-induced long QT syndrome (diLQTS) is the phenomenon by which the administration of drugs causes prolongation of cardiac repolarisation and leads to an increased risk of the ventricular tachycardia known as torsades de pointes (TdP). In most cases of diLQTS, the primary molecular target is the human ether-à-go-go-related gene protein (hERG) potassium channel, which carries the rapid delayed rectifier current ($I_{Kr}$) in the heart. However, the proarrhythmic risk associated with drugs that block hERG can be modified in patients by a range of environmental- and disease-related factors, such as febrile temperatures, alterations in pH, dyselectrolytaemias such as hypokalaemia and hypomagnesemia and coadministration with other drugs. In this review, we will discuss the clinical occurrence of drug-induced LQTS in the context of these modifying factors as well as the mechanisms by which they contribute to altered hERG potency and proarrhythmic risk.

Keywords Arrhythmia · hERG · Hypokalaemia · Hypomagnesemia · Febrile · Acidosis

Drug-induced long QT syndrome

Drug-induced (diLQTS) or acquired long QT syndrome (aLQTS) is characterised by prolongation of the QT interval on the surface electrocardiogram (ECG) and is associated with a markedly increased risk of the potentially lethal ventricular arrhythmia known as torsades de pointes (TdP) (Roden 2004). A prospective study of hospital admission for drug-induced TdP reported 3.3 cases per million over the 4-week study period, translating to an annual incidence of 4/100,000 (Darpö 2001). However, this may be an underestimate for the broader population since TdP is often not reported in out-of-hospital cases (Birda et al. 2018; Lin et al. 2020; Yu et al. 2017). For hospitalised patients, the prevalence of severe diLQTS has been reported as between 1.6 and 3.3% of patients (Birda et al. 2018; Lin et al. 2020; Yu et al. 2017), with these patients having a higher all-cause mortality than their non-LQTS counterparts (Lin et al. 2020; Yu et al. 2017). Over the past 30 years, a range of cardiac (Kannankeril et al. 2011; Selzer and Wray 1964; Singh et al. 2000) and noncardiac (Schoonmaker et al. 1966) drugs have been shown to prolong the QT interval, with several being recalled from the market (Roden 2004). diLQTS can be caused by drugs that block any of the ion channel currents that contribute to normal cardiac repolarisation. In practice, however, the majority of drugs that cause diLQTS do so by inhibiting hERG/Kv11.1 potassium channels, encoded by the KCNH2 gene, which carries the rapid delayed rectifier $K^+$ current ($I_{Kr}$) in the heart (Vandenberg et al. 2012). This unintentional block of hERG is therefore a problem both for development of new therapeutic compounds, as well as management of patients prescribed such drugs (see Table 1 for a full list of compounds discussed in this review). Consequently, screening for potency of hERG channel block, as a surrogate for QT prolongation and repolarisation delay, is a mandated part of preclinical drug development ((ICH S7B 2005), Fig. 1). However, the link between a drug’s potency to block hERG and the emergence of arrhythmia is complex. Of the majority of new chemical entities, up to 70% in some estimates (Shah 2005) can block hERG at some concentration, yet only a small percentage cause arrhythmia (Darpö 2001, 2007). Moreover, even for drugs that are demonstrably “high risk”, the severity of adverse events across the patient population can be highly variable ranging from minimal prolongation of cardiac repolarisation to the induction of lethal
| Drug name       | Drug class      | Primary target                                                                 | Reference                                                                 |
|-----------------|-----------------|-------------------------------------------------------------------------------|---------------------------------------------------------------------------|
| Amiodarone      | Class III antiarrhythmic | hERG and CACNA2D2* channel                                                    | Du et al. (2011)                                                          |
| Amisulpride     | Antipsychotic   | Dopamine D2 receptor                                                          | Lin et al. (2009)                                                         |
| Astemizole      | Antihistamine   | Histamine H1 receptor                                                         | Yao et al. (2005)                                                         |
| Azimilide       | Class III antiarrhythmic | I(Ks) and hERG channels                                                       | Busch et al. (1998), Dong et al. (2004)                                   |
| Azithromycin    | Macrolide antibiotic | 23 s RNA of the bacterial 50S ribosomal unit pump                             | Delaunois et al. (2021), TeBay et al. (2021), Zequn et al. (2021)         |
| Bepridil        | Antianginal     | L-type calcium channel and Na+/K+-ATPase pump                                 | Windley et al. (2018)                                                    |
| Berberine       | Alkaloid        | Unknown                                                                       | Zhi et al. (2015)                                                         |
| Ceftriaxone      | Cephalosporin antibiotic | Peptidases of the bacterial cytoplasmic membrane                             | Lazzerini et al. (2018)                                                  |
| Chloroquine     | Antimalarial    | Hemozoin                                                                      | Delaunois et al. (2021), TeBay et al. (2021), Warhurst (1986), Warhurst et al. (2003), Zequn et al. (2021) |
| Cisapride       | Gastroprokinetic | Serotonin 5-HT $_4$ receptor                                                  | Barrows, et al. (2009), Kamiya et al. (2008), Lacerda et al. (2001), Lee et al. (2019), Lin et al. (2005c), Perrin et al. (2008), Thomas et al. (1998), Thouta et al. (2018), Windley et al. (2016), Windley et al. (2018) |
| Clarithromycin  | Macrolide antibiotic | 23 s RNA of the bacterial 50S ribosomal unit                                  | Zhi et al. (2015)                                                         |
| Diltiazem       | Antianginal     | L-type calcium channel                                                        | Thomas et al. (1998)                                                     |
| Disopyramide    | Class 1A antiarrhythmic | Fast sodium channels                                                        | Hirose et al. (2008), Lazzerini et al. (2018)                             |
| Dofetilde       | Class III antiarrhythmic | hERG channel                                                                | Du et al. (2011), Perrin et al. (2008), Singh et al. (2000), Wang et al. (2016), West et al. (1997), Yang et al. (2004) |
| Domperidone     | Gastroprokinetic | Dopamine D2 and D3 receptor                                                   | Boyce et al. (2012)                                                      |
| E-4031          | Class III antiarrhythmic | hERG channel                                                                | Wang et al. (1997), West et al. (1997), Yao et al. (2005)                  |
| Enalapril       | Antihypertensive | Angiotensin converting enzyme                                                 | Varriale and Ramaprasad (1995)                                           |
| Encainide       | Class 1c antiarrhythmic | Sodium channel protein type 5 subunit alpha                                  | Echt et al. (1991)                                                      |
| Erythromycin    | Macrolide antibiotic | 23 s RNA of the bacterial 50S ribosomal unit                                  | Delaunois et al. (2021), Guo et al. (2005), Kirsch et al. (2004), Lacerda et al. (2001), Paris et al. (1994) |
| Fentanyl        | Opioid analgesic | µ-opioid receptor                                                            | Tschirhart and Zhang (2020)                                               |
| Flecaïnine      | Class 1C antiarrhythmic | Fast sodium channel                                                          | Du et al. (2011), Echt et al. (1991), Paul et al. (2002)                  |
| Fluoxetine      | Antipsychotic   | Dopamine D1 and D2 receptor                                                   | Lin et al. (2009)                                                        |
| Gentamicin      | Aminoglycoside antibiotic | Lipopolysaccharides and phospholipids and the bacterial cell membrane    | Varriale and Ramaprasad (1995)                                           |
| Glyburide       | Sulfonylurea    | KATP** channels                                                              | Varriale and Ramaprasad (1995)                                           |
| Halofantrine    | Antimalarial    | Unknown                                                                       | Charbit et al. (2002)                                                    |
| Haloperidol     | Antipsychotic   | Dopamine D2 receptor                                                         | Lin et al. (2009)                                                        |
| Hydroxychloroquine | Antimalarial    | Unknown                                                                       | Delaunois et al. (2021), TeBay et al. (2021), Warhurst et al. (2003), Zequn et al. (2021) |
| Ibutilide       | Class III antiarrhythmic | hERG and slow sodium channel                                                 | Lin et al. (2008)                                                        |
| Iboagaine       | Psychoactive/psychedelic | µ-, δ- and κ-opioid receptors, serotonin 5-HT$_{2A}$, HT$_{3C}$, and HT$_{3L}$ receptors, sigma $\sigma_1$ and $\sigma_2$ receptors, NMDA*** receptor, nicotinic acetylcholine (nACh) receptor, serotonin transporter (SERT) and dopamine active transporter (DAT) | Thurner et al. (2014)                                                    |
| Itraconazole    | Antifungal      | 14-α-sterol demethylase of the fungal cell membrane                           | Pohjola-Sintonen et al. (1993)                                            |
arrhythmia (Kannankeril et al. 2011; Singh et al. 2000). A number of factors likely contribute to this variable response, including pre-existing disease resulting in electrical or structural remodelling of the myocardium, sex differences and an

| Drug name       | Drug class       | Primary target                                                                 | Reference                                                                 |
|-----------------|------------------|--------------------------------------------------------------------------------|----------------------------------------------------------------------------|
| Ketoconazole    | Antifungal       | 14-α-sterol demethylase of the fungal cell membrane                            | Boyce et al. (2012) Rajput et al. (2010), Yao et al. (2005)                |
| Lopinavir       | Antiretroviral   | HIV-1 protease enzyme                                                           | Zequn et al. (2021)                                                       |
| Loratadine      | Antihistamine    | H1 histamine receptor                                                           | Lacerda et al. (2001)                                                     |
| Moxifloxacin    | Fluoroquinolone antibiotic | Topoisomerase II (DNA gyrase) and topoisomerase IV of the bacteria | Alexandrou et al. (2006)                                                  |
| Posaconazole    | Antifungal       | 14-α-sterol demethylase of the fungal cell membrane                            | Panos et al. (2016)                                                      |
| Prednisolone    | Glucocorticoid   | Phospholipase A2                                                               | Hirose et al. (2008)                                                     |
| Quinidine       | Class I antiarrhythmic | L-type calcium, hERG, slow IKs and KATP** channels | Ayad et al. (2010), Barrows et al. (2009), Dong et al. (2004), Paul et al. (2002), Po et al. (1999), Roden et al. (1986), Selzer and Wray, (1964), Yang et al. (1997) |
| Quinine         | Alkaloid/antimalarial | Unknown                                                                 | Warhurst (1986)                                                           |
| Risperidone     | Antipsychotic    | Dopaminergic D2 and serotonin 5-HT2A receptors                                  | Lin et al. (2009)                                                         |
| Ritonavir       | Antiretroviral   | HIV protease inhibitor                                                          | Zequn et al. (2021)                                                       |
| Terfenadine     | Antihistamine    | Histamine H1-receptor                                                           | Kamiya et al. (2008), Lacerda et al. (2001), Paris et al. (1994), Perrin et al. (2008), Pohjola-Sintonen et al. (1993), Rajput et al. (2010), Thouta et al. (2018), Windley et al. (2018), Yao et al. (2005) |
| Thioridazine    | Antipsychotic    | Dopamine D1 and D2 receptors                                                    | Schoonmaker et al. (1966)                                                |
| Vancomycin      | Glycopeptide antibiotic | Peptidoglycan matrix inhibitor of the bacterial cell membrane | Varriale and Ramaprasad (1995)                                           |
| Verapamil       | Class IV antiarrhythmic | L-type calcium channel                                                         | Windley et al. (2018), Zhang et al. (1999)                               |

*a Calcium voltage-gated channel auxiliary subunit alpha2 delta2 gene protein.**ATP-sensitive K+ channel.***N-methyl-D-aspartate receptor

Fig. 1 Summary of environmental effects on drug potency. Many disease factors are known to shift the potency of drugs blocking hERG, such as fever, hypokalaemia, hypocalcaemia, etc. a A theoretical hERG tail current with scale indicated for current amplitude and time, as elicited by the protocol in the above insert. The black trace represents a control current evoked in drug-free conditions, with the blue trace representing 50% inhibition of the current evoked by a theoretical drug. A condition leading to less potent drug inhibition is represented in green, showing only 25% inhibition, with a condition leading to greater potency leading to 75% inhibition and as depicted in red. b A theoretical concentration response curve, with the main drug effect represented in blue. A condition creating lesser potency would lead to a rightward shift, as indicated in green, and, on an ECG, would lead to less QT prolongation, as seen in the insert and depicted in green. Conditions leading to greater potency are depicted in red, and would shift leftward and, on an ECG, would lead to more prolongation, as seen in the insert and as depicted in red. Assets for the ECG traces obtained from Servier Medical Art (Servier 2021)
individual’s genetic background (Echt et al. 1991; Makkar et al. 1993; Roden and Viswanathan 2005). Aside from these patient-specific factors, a drug’s proarrhythmic propensity can also be modified by other systemic/acquired factors in patients such as electrolyte disturbances, acidosis, febrile temperatures and coadministration with other drugs. The importance of such considerations has been highlighted recently in relation to repurposing of drugs for treatment of COVID-19. Specifically, various combinations of drugs that are known to carry some degree of proarrhythmic risk, including chloroquine, hydroxychloroquine, azithromycin, erythromycin and lopinavir/ritavir, have been proposed as potential therapies (Delaunois et al. 2021; Zequn et al. 2021) in COVID-19 patients where fever (Aslam et al. 2021; Pan et al. 2020; Zhou et al. 2020), acidosis (Zhou et al. 2020) and electrolyte disturbances (Alfano et al. 2021; Lippi et al. 2020; Stevens et al. 2021) were also reported. Here, we will review both the clinical occurrence of diLQTS in the context of fever, hypokalaemia, hypomagnesaemia and other electrolyte disturbances and the mechanisms by which these factors contribute to altered potency of hERG block and proarrhythmic risk.

### Effect of kalaemic variation on drug-induced long QT syndrome

Potassium is the most abundant intracellular cation, which in healthy patients exists within the range of 3.6–5.0 mM in the plasma (El-Sherif and Turitto 2011; Salzman 2018). In the case of altered serum potassium, hypokalaemia is the most common electrolyte abnormality, occurring in over 20% of hospitalised patients, and is defined as a plasma K+ level of less than 3.6 mM. This occurs most frequently as a result of decreased intake, increased renal or gastrointestinal loss or via transcellular shift (El-Sherif and Turitto 2011; Salzman 2018). Hyperkalaemia (plasma K+ > 5.0 mM) is less common, reported in 8% of hospitalised patients, and occurs as a result of potassium-sparing diuretic use, higher intake, decreased excretion due to renal failure or damage or transcellular shift of potassium into the extracellular environment (El-Sherif and Turitto 2011; Salzman 2018). In patients taking drugs with established proarrhythmic risk, changes in serum K+ have been observed to drive further QT prolongation and incidence of TdP. For example, Ayad et al. reported the case of a patient taking quinidine for 15 years without any incidence of QT prolongation who developed TdP and syncope as a result of hypokalaemia by way of gastrointestinal loss (Ayad et al. 2010). Similarly, in a study of 24 individuals, patients administered hERG blockers such as quinidine while taking potassium-depleting diuretics were identified to be at higher risk for QT prolongation and development of TdP, although some of these patients also presented with several other risk factors such as hypertension, cardiomyopathy or were also taking additional QT prolonging drugs (Roden et al. 1986). However, hypokalaemia rarely presents alone, meaning other parallel factors can also contribute to QT prolongation. In a study of 11 patients in whom diLQTS was present, including 8 who exhibited severe hypokalaemia, additional factors such as hypomagnesaemia, hypertension and alcohol use were also present (Digby et al. 2011), while in a larger study of 804 chronic kidney disease patients, lower serum K+ and Ca2+ were each found to be significant contributors to QT prolongation, often against a background of chronic diseases such as hypertension or diabetes (Liu et al. 2019).

#### Mechanism of kalaemia-dependent changes in hERG block and QT prolongation

Understanding the relationship between kalaemic variation and drug-induced prolongation of repolarization is complex, since variation in extracellular potassium has direct effects on cardiac repolarization, via effects on potassium channel function and expression, as well as drug binding (Barrows et al. 2009; Guo et al. 2009, 2011; Limbers et al. 2006; Melgari et al. 2014; West et al. 1997; Yang et al. 2004, 1997). Here we will focus on studies that have specifically addressed potassium dependence of a drug’s potency to block hERG. Across the literature, reports of the influence of K+ on potency to block hERG across drugs is broadly consistent, with increasing extracellular potassium reducing the potency of block (Barrows et al. 2009; Busch et al. 1998; Lin et al. 2007, 2008, 2005c; Lin and Papazian 2007; Mergenthaler et al. 2001; TeBay et al. 2021; Wang et al. 1997; West et al. 1997; Yang et al. 2004) and decreased potassium concentration increasing potency of block (Lin et al. 2005a; TeBay et al. 2021; Tschirhart and Zhang 2020). Two potential mechanisms have been proposed to explain this. First, it has been suggested that changes in the state or conformation of hERG as a function of K+ might impact the potency of drugs that exhibit state-dependent binding. The hERG channel can exist in one of three states: closed, open or inactivated, with two voltage-dependent gates, a fast inactivation gate and a slow activation/deactivation gate (Vandenberg et al. 2012). Some drugs can exhibit “state preference”, showing a greater affinity for either open or inactivated state (Lee et al. 2016, 2019; Perrin et al. 2008; Stork et al. 2007). As a result, changes in conditions such as K+ that is known to alter the equilibrium between the open and inactivated states of the channel can contribute to variation in observed potency for state-dependent drugs. For example, after observing reduced potency across a panel of drugs with inactivated state preference in the presence of elevated K+, Yang et al. posited that the shift away from the inactivated state of the hERG channel that occurs under these conditions...
In reality, it is likely that both mechanisms may contribute, depending on the specific compound. In the current literature, mechanistic studies have generally sampled only small subsets of drugs, often because data has been generated using manual patch-clamp electrophysiology, which limits the throughput and scale of these investigations. To more confidently discern the mechanism by which altered K\(^+\) affects drug potency, it is likely that studies of larger drug panels are required, which could be facilitated using high-throughput platforms such as automated patch-clamp or radioligand binding assays. For example, Diaz et al. used \(^3\)H dofetilide binding assay to assess a panel of 56 compounds, showing that higher K\(^+\) lead to reduced potency for some compounds, though increased potency for others (Diaz et al. 2004) — inconsistent with the broad trend reported in prior patch-clamp studies. However, in comparison with the gold standard of manual patch clamp, there was a greater than 5- to sixfold difference between potencies measured in binding versus patch clamp for some compounds, with 6 of those compounds having greater than tenfold difference (Diaz et al. 2004). In resolving this question, the use of automated patch-clamp platforms, which combine throughput with gold standard electrophysiology, is likely the technology that will facilitate the scale and quality of information required for interpreting and predicting the clinical implications of K\(^+\) on hERG drug block and proarrhythmic risk into the future.

**Effects of divalent ions on drug-induced long QT syndrome**

**Clinical observations for altered serum divalent concentration**

Two divalent cations that are (i) present in human plasma at concentrations relevant for modification of hERG function and/or block, and (ii) have altered concentrations in pathological states, are magnesium and calcium. In healthy patients, normal total plasma calcium concentration is in the range 2.2–2.55 mM, where concentrations outside of this range, typically lower, can contribute to QT prolongation and hence arrhythmic risk (Liu et al. 2019; Nijjer et al. 2010; Szymanski et al. 2013). However, free- or ionised-calcium concentrations are significantly lower (1.05–1.3 mM (Goldberg 2019)), due to binding to plasma proteins such as albumin (Labriola et al. 2009), making this the preferred clinical measurement in predicting prolongation of the QT interval (Kim et al. 2019) and a more suitable comparison for in vitro experiments than total Ca\(^{2+}\). Hypocalcaemia can be observed with renal insufficiency, parathyroid disease, reduced intake, acute pancreatitis, septic shock or other electrolyte disturbances, whereas hypercalcaemia is associated with hyperparathyroidism, vitamin D disturbances, endocrine disorders,
neoplastic disorders and many other malignancies (El-Sherif and Turitto 2011; Salzman 2018). For magnesium, the normal range is 0.7–0.95 mM, and while both hypomagnesemia and hypermagnesemia can result in QT interval prolongation (Topf and Murray 2003), their effects on electrophysiology are often hard to ascertain due to their frequent association with other electrolyte or electrophysiological abnormalities (Ayad et al. 2010; El-Sherif and Turitto 2011; Roden et al. 1986; Salzman 2018; Whang and Ryder 1990). Hypomagnesemia is common, especially in geriatric populations, and can occur due to decreased gastrointestinal uptake or renal loss, whereas hypermagnesemia is far rarer, especially outside of an obstetric population, given the large reserve of magnesium excretion potential the kidneys possess, often only occurring in the background of renal failure (El-Sherif and Turitto 2011; Topf and Murray 2003).

Mechanism of divalent ion-dependent changes in hERG block

While there is significant literature on the effect of divalent cations on cardiac electrophysiology and hERG channel
function, there are fewer comprehensive reports on divalent cation dependence of hERG drug block potency. Furthermore, the literature that does exist presents a somewhat inconsistent narrative. Increased extracellular Mg$^{2+}$ has been shown to increase the potency of hERG block for multiple compounds (Po et al. 1999; TeBay et al. 2021), whereas reduced internal Mg$^{2+}$ was found to reduce the potency of quinidine (Yang et al. 1997). Conversely, concentrations of extracellular Ca$^{2+}$ between 0.1 and 10 mM did not modify the block of either quinidine or cisapride (Barrows et al. 2009). Since there are suggestions that divalent ions could act as hERG/IKr blockers themselves, with binding sites identified within the hERG channel (Anumonwo et al. 1999; Ho et al. 1996, 1998, 1999), one potential mechanism could be that divalent ions together with hERG blocking drugs could result in an increased overall load of IKr inhibition (Po et al. 1999). Another potential explanation is that divalent ions regulate the deactivation kinetics of hERG, which could in turn affect drug dissociation and the degree to which some drugs exhibit “drug trapping” (Barrows et al. 2009). One factor that has confounded in vitro investigations in this area is the need for 1–2 mM concentrations of calcium in bath solutions for patch-clamp electrophysiology, which is critical for formation and maintenance of high-quality seals (Lin and Papazian 2007). As a result, investigations of the effects of variation in divalent ion concentrations in the physiological range are limited in these systems. This issue is particularly salient in automated high-throughput patch-clamp systems, where calcium fluoride seal enhancers are critical in establishing high-quality seals (Braun et al. 2021), meaning thorough investigation of the effects of divalent ions on drug block of hERG at large scale remains technically difficult. In addition to this practical challenge, there is also the issue of what is physiologically or clinically relevant. While observing the effects of wide ranges in concentration of divalent ions may be mechanistically interesting, calcium and particularly magnesium exist in narrow physiological ranges, meaning the clinical relevance of such studies are limited.

### Acidosis and alkalosis

#### Effect of acidosis and alkalosis on drug-induced QT prolongation

Metabolic acidosis can increase the QT interval on the ECG (Yenigun et al. 2016) as well as lower the threshold for ventricular fibrillation. Such changes can become particularly problematic in the case of localised changes in pH surrounding ischemic regions of the heart, which produce heterogeneity in action potential duration and provide an electrical substrate for re-entry (Clayton and Holden 2005; Gebert et al. 1971; Podrid and Myerburg 2005; Surawicz 1985). Of specific relevance to this review, acidosis has also been reported as a comorbidity in cases of diLQTS (Riezzo et al. 2009). In relation to hERG channels, changes in pH can directly affect hERG function (Anumonwo et al. 1999; Jiang et al. 1999; Jo et al. 1999; Lin et al. 2005a; Shi et al. 2014; Van Slyke et al. 2012; Vereecke and Carmeliet 2000) as well as the molecular pharmacology of the drug channel interaction. In the latter case, early experiments showed that a reduction in pH to 6.8 could significantly reduce hERG block by doxetilde (West et al. 1997). Across numerous subsequent reports, there is broad consensus that extracellular acidification reduces hERG block by a range of compounds (Du et al. 2011; Lin et al. 2005a, b, 2008; TeBay et al. 2021; Thurner et al. 2014; Tschirhart and Zhang 2020; Wang et al. 2016; Zhang et al. 1999), with alkalisation enhancing drug block (Lin et al. 2005a; Thurner et al. 2014; Tschirhart and Zhang 2020; Zhang et al. 1999). There is however some complexity to this relationship since quite different results were seen when the extracellular solution was acidified using sodium acetate rather than hydrochloric acid. In this case,
while lowered pH still reduced block by quinidine and azimilide, the potency of dofetilide was increased (Dong et al. 2004), with the authors suggesting this perhaps occurred because sodium acetate reduced the intracellular (as well as extracellular) pH (Dong et al. 2004). Furthermore, in experiments examining acidification of the intracellular space, while extracellular pH was maintained in the physiological range, dofetilide, flecainide and amiodarone’s block was not diminished when the drugs were applied extracellularly (Du et al. 2011), while for ibogaine, intracellular application of the drug in the presence of intracellular acidification greatly increased the extent of block (Thurner et al. 2014).

**Mechanism of pH effects on hERG block**

Despite differences in drug class and chemical structure of compounds that block hERG, a common explanation for the effect of pH on drug potency has emerged, based on how charge on the functional groups of a drug molecule affects their partition coefficients and hence their ability to cross the cell membrane. For example, antimalarial drugs such as quinine and chloroquine are weak bases and can gain or lose protons from their amino groups depending on pH (Warhurst 1986). In their neutral form, these compounds are lipophilic, with a high partition coefficient (logP), and hence are able to cross the membrane to access their intracellular binding site. However, in more acidic environments, these molecules become protonated, more hydrophilic/lipophobic and less membrane permeable, limiting access to their intracellular binding site and reducing the observed degree of block (Warhurst 1986; Warhurst et al. 2003) (Fig. 1b). Consistent with this, it has been seen that a drug’s potency to block hERG increases with lipophilicity, as measured by logP, or basicity, as measured by pKa (Kawai et al. 2011), while several studies of individual compounds also support this mechanism. For example, Zhang et al. calculated that for verapamil, with a pKa around 8.8, 4% of molecules would exist in a neutral form at pH 7.4, compared to 28% at pH 8.4 and 0.4% at pH 6.4, and observed a corresponding reduction in the potency of block as pH was decreased in vitro (Zhang et al. 1999). The authors also demonstrated that block by N-methyl-verapamil, a permanently charged analogue of verapamil, was not sensitive to changes in pH, confirming that the effect on block was specifically due to the charge on the drug molecule (Zhang et al. 1999). Similar explanations have also been posed for other drugs such as flecainide (Du et al. 2011), ibogaine (Thurner et al. 2014), fentanyl (Tschirhart and Zhang 2020) and hydroxychloroquine (TeBay et al. 2021) supporting the case that this is a common mechanism for the effect of pH on a drug’s potency to block ERG.

For some drug molecules, however, the picture can be more complicated. Dofetilide has multiple functional groups with different pKa values, including two methanesulfonamide groups, with pKa values of 9.0 and 9.6, as well as a nitrogen atom with a pKa of 7, making it a zwitterion (Du et al. 2011). At a pH of 7.4, 2.5% and 0.6% of the methanesulfonamide moieties are charged, compared with 28.5% of amine groups (Du et al. 2011), while at pH 6.3, 0.2% and 0.06% of the methanesulfonamide and 84% of the amine groups would be charged. Thus, the overall effect of acidic pH is a more charged, membrane impermeant molecule that shows reduced block of hERG at lower pH (Du et al. 2011). Other drugs have pKa values outside of the physiological/pathophysiological range but can also exhibit modified potency of hERG block with respect to pH. For example, flecainide, with a pKa of 9.3, exists in 1.2% and 0.1% neutral form at pH 7.4 and 6.3, respectively (a 12-fold difference), so still exhibits significant changes in observed potency between these pH values. Conversely, at the other extreme, amiodarone has a pKa of 5.6 (98% neutral at pH 7.4 and 83% at pH 6.3) and is not sensitive to pH changes in the same range (Du et al. 2011). Finally, for some drugs such as ibogaine, this same mechanism can also result in internal accumulation of a drug molecule, where under low intracellular pH the drug molecule becomes ionised, and hence trapped within the cell, thus increasing the apparent potency of the drug (Fig. 2b) (Thurner et al. 2014).

In addition to the effect of pH via charge on the drug molecule, a further layer of nuance exists in understanding how environmental pH can alter a drug’s potency to block hERG. In a similar manner to extracellular potassium, pH can also affect hERG channel function and hence influences state-specific drug-channel interactions. Specifically, acidosis is known to accelerate hERG deactivation, affecting the occupation of the open state at a given voltage (Anumonwo et al. 1999; Jiang et al. 1999; Jo et al. 1999; Vereecke and Carmeliet 2000) (Fig. 2a). In relation to this, the neutral form of dofetilide has been reported to preferentially bind to the open state of the hERG channel, while the cationic form preferentially binds to the inactivated state (Wang et al. 2016). Using molecular docking simulations, Wang et al. showed that as the channel transitions between open and inactivated states, there is reorientation of the key residues F656 and Y652 that form the drug binding site. Concomitant with this, cationic dofetilide can change confirmation, bringing its benzene rings closer in an event known as π-π stacking, which allows the dofetilide molecule to bind to the channel and stabilise hERG in the inactivated state (Wang et al. 2016). Therefore, overall, a range of factors including the pKa of the compound, the pH of the extracellular versus intracellular environment, passage to the compounds intracellularly accessed binding site and the compound’s state preference all contribute to the pH effect on hERG block in a compound-specific manner. Furthermore, in the physiological/pathophysiological range of pH, significant changes in
hERG block, and hence QT prolongation, can occur, making this an important factor for consideration in relation to diLQTS.

Temperature

Effect of febrile temperature on hERG block and drug-induced long QT syndrome

Elevated/febrile body temperature, as a result of illness and infection, is known to alter or exacerbate diLQTS phenotypes in patients. Perhaps, most commonly, this occurs in association with the use of antibiotics such as vancomycin and gentamicin (Varriale and Ramaprasad 1995), or antifungals such as posaconazole (Panos et al. 2016), to treat infection. However, febrile temperatures are also associated with other pathophysiological conditions such as hypertension and diabetes mellitus in patients who may also be prescribed drugs with potential to prolong the QT interval such as enalapril and glyburide, respectively (Varriale and Ramaprasad 1995). In vitro studies that are specific to febrile versus physiological temperature are limited, with inconsistent reports across different drugs. Erythromycin, for example, has been shown to be a more potent hERG blocker at physiological (37 °C) as opposed to ambient (22 °C) temperature, with further increased potency observed at febrile temperatures (42 °C) (Guo et al. 2005). In contrast, for moxifloxacin, no significant change in potency was observed between physiological temperature and 42 °C (Alexandrou et al. 2006). Similarly, our investigations showed that febrile temperature significantly increased the potency of azithromycin as compared to physiological temperatures, while for chloroquine and hydroxychloroquine, potency was significantly reduced (TeBay et al. 2021). Further insights into the effect of temperature on hERG block can be gleaned from experiments performed at subfebrile temperatures, which are far more common in the literature. Lacerda et al. reported that physiological temperatures (35 °C) evoked only a slight change in potency for terfenadine and loratadine (increase or decrease respectively), with no significant changes observed for cisapride and erythromycin when compared to ambient temperature (Lacerda et al. 2001). Contrary to this, other studies report significant effects of temperature on block of hERG by erythromycin (~ sevenfold increase in potency) (Kirsch et al. 2004) — a difference perhaps is a result of the different voltage protocols used between the two studies. In relation to this, Kirsch noted that at 22 °C, erythromycin did not reach steady state of block when employing a 2-s step pulse protocol with a 10-s interval, leading to an inaccurate estimate of IC50, while at physiological temperature, the true steady state was reached, because of the faster onset of block. This raises an important point that is equally applicable to any studies assessing hERG potency — that there is no “gold standard” protocol and the observed degree of block can be protocol specific. As a result, this potentially confounding factor should be considered in any comparison between studies, such as those described in this review. Overall, then it is clear from the literature that the effect of temperature on potency is compound specific, meaning consideration of the proarrhythmic risk associated with administration of potentially QT prolonging drugs to patients with fever needs to be made on a drug-by-drug basis.

How does temperature modify potency of block?

In a similar manner to kalaemic variation, experiments examining the temperature dependence of the potency of hERG block have suggested two potential mechanisms to explain temperature sensitivity: first, through modification of hERG channel function, particularly in relation to binding of state-dependent drugs, and, second, through direct effect on drug interaction with its binding site on the channel protein. In relation to the first of these, hERG electrophysiology displays complex temperature dependence, with increasing temperature causing a negative shift in the voltage dependence of activation, in concert with a positive shift in the voltage dependence of inactivation (Van denberg et al. 2006), resulting in an overall increased occupancy of the open state at physiological voltages (Fig. 2a). For compounds that exhibit state-dependent binding, these temperature-dependent shifts in state occupancy therefore have potential to affect the measured potency of block. In this regard, Yao et al. investigated the effects of temperature on hERG block by probing state-dependent inhibition with various voltage protocols and temperatures. For astemizole, overall decreased potency was observed at higher temperature, with the greatest degree of block observed with a non-state selective protocol, suggesting that astemizole is able to block multiple states of hERG (Yao et al. 2005). Both terfenadine and ketoconazole similarly showed little preference between protocols optimised for close- or open-state occupancy and, consistent with that, showed little change in potency at higher temperatures. Finally, while E-4031 exhibited open-state preference during ambient temperature recordings, no change in potency was observed at higher temperatures (Yao et al. 2005). The relationship between channel state occupancy, temperature and channel block is therefore complex and requires further experiments across a wider selection of compounds to fully resolve.

The second possible explanation for the effect of temperature on hERG potency — a direct impact of temperature on drug binding kinetics — has been probed using combinations of fast perfusion systems, voltage protocols and in silico modelling. Using ultra-fast solution exchange systems, Windley et al. were able to directly measure both the onset
of block and washout of cisapride, showing that the kinetics of both drug binding and dissociation were temperature sensitive and that complex characteristics of kinetics at higher temperatures could be explained by an accumulation of drug in an intermediate, non-blocking state (termed an encounter complex). Furthermore, they showed that in the context of the cardiac action potential, these temperature-dependent effects on drug binding kinetics were important in predicting the degree of prolongation associated with hERG block (Windley et al. 2016). Following this, a study of a broader range of drugs including verapamil, cisapride, bepridil and terfenadine found that while increasing temperature accelerated the observed onset of block (τ_{on}) for all drugs, the temperature dependence of association and dissociation rates was compound specific (Windley et al. 2018). Furthermore, while there was no significant effect of temperature on measured potency in steady-state block assays, the alterations to the kinetic parameters alone still resulted in variable temperature dependence of the predicted degree of action potential prolongation for each of the drugs (Windley et al. 2018). Overall, this data therefore supports the need to consider the influence of temperature on the kinetics of drug block, even in the absence of changes to potency, in relation to diLQTS. Furthermore, since the effects of temperature appear to be compound specific, pharmacological screening data for use for risk prediction in diLQTS should where possible be acquired at physiological temperatures.

**Drug coadministration**

While most in vitro studies focus on the effect of a single environmental factor on hERG potency, the reality in relation to QT prolongation in the clinical setting is more complex. Patients are often administered multiple drugs with potential to prolong repolarisation, in the background of combinations of electrolyte disturbances and/or chronic disease states (Ayad et al. 2010; Digby et al. 2010). For example, in a study by Digby et al., subjects were prescribed on average 2.8 QT prolonging drugs in the background of diseases including hypertension and dilated cardiomyopathy (Digby et al. 2011). Similarly, in a study of 48 patients hospitalised for TdP, the mean medication number per patient, including QT prolonging drugs in some instances, was 1.1, with electrolyte imbalances seen in 79% of patients (Lazzerini et al. 2018). This data therefore highlights the importance of considering how drugs might interact with each other, either directly or indirectly in understanding QT prolongation in patients.

Regarding direct drug effects, the simplest consideration is that of an additive effect on hERG block. Most drugs that block hERG are thought to share a common binding site formed by a network of aromatic residues in the vestibule of the channel (Kamiya et al. 2008; Stansfeld et al. 2006). Given this common binding site, a patient taking multiple QT prolonging agents could simply be considered to have an increased load of hERG channel block — so increasing their potential for QT prolongation and TdP. In patients, these additive effects have most often been reported in association with coadministration of antipsychotic drugs. Lin et al. reported a patient presenting with schizophrenia who was prescribed risperidone, amisulpride and haloperidol, leading to sudden cardiac arrest, where discontinuation of amisulpride leads to a gradually normalised QTc interval (Lin et al. 2009). In the same study, the authors also described a second patient who developed a QTc interval of 510 ms when co-administered amisulpride and flupenthixol, with neither agent alone producing concerning QT prolongation (Lin et al. 2009).

Aside from additive effects on hERG block, coadministration of drugs can also result in increased torsadogenicity via effects on drug metabolism. Increasing concentrations of berberine or clarithromycin have been shown to significantly inhibit activity of cytochrome P450 enzymes of the CYP3A family in vitro. Since this enzyme is a major metaboliser of many QT prolonging drugs, this reduction in CYP3A activity can lead to altered pharmacokinetics and hence a greater plasma concentration of either drug (Zhi et al. 2015). This link between inhibition of drug metabolism and proarrrhythmia has been observed across multiple studies including reports that ketoconazole, erythromycin, diltiazem, itraconazole and grapefruit juice — all inhibitors of cytochrome P450 enzymes — have resulted in increased serum concentration of terfenadine, halofantrine and cisapride, leading to QT prolongation and TdP (Charbit et al. 2002; Paris et al. 1994; Pohjola-Sintonen et al. 1993; Rajput et al. 2010; Thomas et al. 1998). This phenomenon has also been detected in larger cohorts where coadministration of ketoconazole with dopaminedone was found to triple the plasma concentration of domperidone, exacerbating QTc prolongation to clinically significant levels, over and above that observed for either agent alone (Boyce et al. 2012).

Systemic effects induced by other drugs have also been seen to modify the risk profile of QT prolonging compounds. For example, Roden et al. described cases where hypokalaemia caused by potassium-depleting diuretics were found to exacerbate quinidine-induced QT prolongation (Roden et al. 1986), while incidences of hypomagnesemia caused by protein pump inhibitor usage, in combination with QT prolonging medications such as ceftriaxone or disopyramide, were shown to trigger TdP (Lazzerini et al. 2018). Finally, another case described a patient treated with prednisolone for myasthenia gravis precipitating atrial fibrillation, which was in turn treated with disopyramide. The disopyramide administration resulted in worsening myasthenia gravis, leading to respiratory failure and serum disturbances including...
alkalosis and hypokalaemia, which together precipitated TdP (Hirose et al. 2008). Together, these cases demonstrate that regardless of the mechanism of their interaction, the simultaneous presence of multiple hERG blocking agents, and their interaction with systemic factors such as electrolytes, have clear potential to increase proarrhythmic risk, and patients should be monitored appropriately when QT prolonging medicines are co-administered.

Conclusions

In order to understand or predict the occurrence of drug-induced QT prolongation and TdP in patients, it is clear that risk allocation is far more complicated than a static label assigned to individual drugs. Rather, a range of pathophysiological factors associated with disease states as well as coadministration with other drugs need to be considered when prescribing and managing the risk of therapeutics with potential to prolong the QT interval. While significant literature exists describing how factors such as pH, fever and kalaemic variation affect potency to block hERG, there are still gaps in our knowledge regarding the mechanisms of these effects, which may be better addressed via studies on more extensive drug libraries that are now feasible as a result of the increased use of high-throughput automated patch-clamp screening platforms. Furthermore, incorporation of data from these large-scale screens into population models of cardiac electrophysiology (TeBay et al. 2021; Varshneya et al. 2021) will help us better understand the relationships between a drug’s ion channel blocking potency, the effect of environmental modifiers, genetic background and risk of TdP.

Author contribution

Clifford TeBay and Monique Windley contributed to the conception and design. Clifford TeBay performed the literature review and wrote the first draft. All authors critically revised the manuscript. All authors approved the final manuscript.

Funding

Open Access funding enabled and organized by CAUL and its Member Institutions. Clifford TeBay is supported through an Australian Government Research Training Program Scholarship. Monique Windley is supported by an Australian National Health and Medical Research Council project grant to Adam Hill (GNT1164518).

Declarations

Ethics approval and consent to participate. Not applicable.

Consent for publication. Not applicable.

Conflict of interest The authors declare no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

Alexandrou AJ, Duncan RS, Sullivan A, Hancox JC, Leishman DJ, Witchel HJ, Leaney JL (2006) Mechanism of hERG K+ channel blockade by the fluoroquinolone antibiotic moxifloxacin. Br J Pharmacol 147:905–916. https://doi.org/10.1038/sj.bjp.0706678

Alfano G, Ferrari A, Fontana F, Perrone R, Mori G, Ascione E, Magistroni R, Venturi G, Pederzoli S, Margiotta G, Romeo M, Piccinni F, Franceschi G, Volpi S, Flatoni M, Ciusa G, Baccia E, Tutone M, Raimondi A, Menozzi M, Franceschini E, Cuomo G, Orlandi G, Santoro A, Di Gaetano M, Pazzolante C, Carli F, Bedini A, Milic J, Meschiari M, Mussini C, Cappelli G, Guarraldi G (2021) Hypokalemia in patients with COVID-19. Clin Exp Nephrol 25:401–409. https://doi.org/10.1007/s10157-020-01996-4

Anumonwo JM, Horta J, Delmar M, Taffet SM, Jalife J (1999) Proton and zinc effects on hERG currents. Biophys J 77:282–298. https://doi.org/10.1016/S0006-3495(99)76889-X

Aslam W, Lamb CR, Ali N (2021) Torsades de pointes in SARS-CoV-2 (COVID-19) pneumonia: medicine reconciliation and careful monitoring of QTc interval may help prevent cardiac complications. BMJ Case Rep 14:e239963. https://doi.org/10.1136/bcr-2020-239963

Ayad RF, Assar MD, Simpson L, Garner JB, Schussler JM (2010) Causes and management of drug-induced long QT syndrome. Proc (baylor Univ Med Cent) 23:250–255. https://doi.org/10.1080/08998280.2010.11928628

Barrows B, Cheung K, Bialobrzeski T, Foster J, Schulze J, Miller A (2009) Extracellular potassium dependency of block of hERG by quinidine and cisapride is primarily determined by the permeant ion and not by inactivation. Channels (austin) 3:239–248. https://doi.org/10.4161/chan.3.4.9254

Birda CL, Kumar S, Bhatta A, Sharma N, Kumari S (2018) Prevalence and prognostic significance of prolonged QTc interval in emergency medical patients: a prospective observational study. Int J Crit Illn Inj Sci 8:28–35. https://doi.org/10.4103/IJCIS.IJCIS_59_17

Boyce MJ, Baisley KJ, Warrington SJ (2012) Pharmacokinetic interaction between domperidone and ketoconazole leads to QT prolongation in healthy volunteers: a randomized, placebo-controlled, double-blind, crossover study. Br J Clin Pharmacol 73:411–421. https://doi.org/10.1111/j.1365-2125.2011.04093.x

Braun N, Friis S, Ilining C, Sinz A, Andersen J, Pless SA (2021) High-throughput characterization of photocrosslinker-bearing ion channel variants to map residues critical for function and pharmacology. PLoS Biol 19:e3001321. https://doi.org/10.1371/journal.pbio.3001321

Busch AE, Eigenberger B, Jurkiewicz NK, Salata JJ, Pica A, Suessbrich H, Lang F (1998) Blockade of hERG channels by the class III antiarrhythmic azimilide: mode of action. Br J Pharmacol 123:23–30. https://doi.org/10.1038/sj.bjp.0701575
concentrations. Nephrol Dial Transplant 24:1834–1838. https://doi.org/10.1093/ndt/gfn747

Lacerda AE, Kramer J, Shen KZ, Thomas D, Brown AM (2001) Comparison of block among cloned cardiac potassium channels by non-antiarhythmic drugs. Eur Heart J Suppl 3:K23–K30. https://doi.org/10.1016/S1290-765X(01)00063-3

Lazzerini PE, Bertolozzi I, Finizola F, Acampa M, Natale M, Vanni F, Fulcieri R, Gamberucci A, Rossi M, Giabbanì B, Caselli M, Lamberti I, Cevenini G, Laghi-Pasini F, Capecci PL (2018) Proton pump inhibitors and serum magnesium levels in patients with torsades de pointes. Front Pharmacol 9:363. https://doi.org/10.3389/fphar.2018.00363

Lee W, Mann SA, Windley MJ, Imtiaz MS, Vandenberg JJ, Hill AP (2016) A novel assessment of kinetics and state dependent binding properties of drugs causing acquired LQTS. Prog Biophys Mol Biol 120:89–99. https://doi.org/10.1016/j.pbiomolbio.2015.12.005

Lee W, Windley MJ, Perry MD, Vandenberg JJ, Hill AP (2019) Protocol-dependent differences in IC50 values measured in human ether-a-go-go-related gene assays occur in a predictable way and can be used to quantify state preference of drug binding. Mol Pharmacol 95:537–550. https://doi.org/10.1124/mol.1186.115220

Limberis JT, Su Z, Cox BF, Gintant GA, Martin RL (2006) Altering extracellular potassium concentration does not modulate drug block of human ether-a-go-go-related gene (hERG) channels. Clin Exp Pharmacol Physiol 33:1059–1065. https://doi.org/10.1111/j.1440-1681.2006.04487.x

Lin MC, Papazian DM (2007) Differences between ion binding to eag and HERG voltage sensors contribute to differential regulation of activation and deactivation gating. Channels (Austin) 1:429–437. https://doi.org/10.4161/chan.1.6.5760

Lin C, Cvetanovic I, Ke X, Ranade V, Somberg J (2005a) A mechanism for the potential proarrhythmic effect of acidosis, bradycardia, and hypokalemia on the blockade of human ether-a-go-go-related gene (HERG) channels. Am J Physiol 12:328–336. https://doi.org/10.1097/01.mjt.0000143698.53038.1b

Lin C, Ke X, Cvetanovic I, Ranade V, Somberg J (2005b) The influence of extracellular acidosis on the effect of IKr blockers. J Cardiovasc Pharmacol Ther 10:67–76. https://doi.org/10.1177/107424840501000108

Lin J, Guo J, Gang H, Wojciechowski P, Wigle JT, Zhang S (2005c) Intracellular K+ is required for the inactivation-induced high-affinity binding of cisapride to HERG channels. Mol Pharmacol 68:855–865. https://doi.org/10.1124/mol.105.012278

Lin C, Ke X, Cvetanovic I, Ranade V, Somberg J (2007) The effect of high extracellular potassium on IKr inhibition by anti-arrhythmic agents. Cardiology 108:18–27. https://doi.org/10.1159/000095596

Lin C, Ke X, Ranade V, Somberg J (2008) Extracellular acidification and hyperkalemia induce changes in HERG inhibition by ibutilide. Cardiology 110:209–216. https://doi.org/10.1159/00011932

Lin Y, Sun IW, Liu SI, Chen CY, Hsu CC (2009) QTc prolongation during concurrent treatment with depot antipsychotics and high-dose amisulpiride: a report of 2 cases. J Intern Med Taiwan 20:544–549

Lin Y, Yu H, Liu F, Chen C, Zhang Y, Wang B, Yang Y, Liu Y, Zhang L, Xia Y (2020) Hospitalized cancer patients with acquired long QT syndrome-a matched case-control study. Cardio Oncology 6:3. https://doi.org/10.1016/j.s40599-020-0057-2

Lippi G, South AM, Henry BM (2020) Electrolyte imbalances in patients with severe coronavirus disease 2019 (COVID-19). Ann Clin Biochem 57:262–265. https://doi.org/10.1177/000456320922255

Liu P, Han D, Sun X, Tan H, Wang Z, Liu C, Zhang Y, Li B, Sun C, Shi R, Li G (2019) Prevalence and risk factors of acquired long QT syndrome in hospitalized patients with chronic kidney disease. J Investig Med 67:289–294. https://doi.org/10.1136/jim-2018-000798

Makkar RR, Fromm BS, Steinmann RT, Meissner MD, Lehmann MH (1993) Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 270:2590–2597. https://doi.org/10.1001/jama.270.21.2590

Melgar D, Du C, El Harchi A, Zhang Y, Hancock JC (2014) Suppression of the hERG potassium channel response to premature stimulation by reduction in extracellular potassium concentration. Physiol Rep 2:e12165. https://doi.org/10.14814/phy2.12165

Mergerhalter J, Haverkamp W, Huttenhofer A, Skyabin BV, Musshoff U, Borggreve M, Speckmann EJ, Breithardt G, Madeja M (2001) Blocking effects of the antiarrhythmic drug propafenone on the HERG potassium channel. Naunyn Schmiedebergs Arch Pharmacol 363:472–480. https://doi.org/10.1007/s002100003392

Nijjer S, Ghosh AK, Dubrey SW (2010) Hypocalcaemia, long QT interval and atrial arrhythmias. BMJ Case Rep 2010:bcr0820092216. https://doi.org/10.1136/bcr.08.2009.2216

Pan L, Mu M, Yang P, Sun Y, Wang R, Yan J, Li P, Hu B, Wang J, Hu C, Jin Y, Niu X, Ping R, Du Y, Li T, Xu G, Hu Q, Tu L (2020) Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study. Am J Gastroenterol 115:766–773. https://doi.org/10.14399/ajg.202000006602

Panos G, Velissaris D, Karamouzou V, Matzaroglou C, Tylianakis M (2016) Long QT syndrome leading to multiple cardiac arrests after posaconazole administration in an immune-compromised patient with sepsis: an unusual case report. Am J Case Rep 17:295–300. https://doi.org/10.12695/ajcr.896946

Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP (1994) Torsades de pointes induced by erythromycin and terfenadine. Am J Emerg Med 12:636–638. https://doi.org/10.1016/0735-1770(94)90029-9

Paul AA, Witchel HJ, Hancock JC (2002) Inhibition of the current of heterologously expressed HERG potassium channels by flecainide and comparison with quinidine, propafenone and lignocaine. Br J Pharmacol 136:717–729. https://doi.org/10.1038/sj.bjp.0704784

Perrin MJ, Kuchel PW, Campbell TJ, Vandenberg JJ (2008) Drug binding to the inactivated state is necessary but not sufficient for high-affinity binding to human ether-a-go-go-related gene channels. Mol Pharmacol 74:1443–1452. https://doi.org/10.1124/mol.107.049056

Po SS, Wang DW, Yang IC, Johnson JP Jr, Nie L, Bennett PB (1999) Modulation of HERG potassium channels by extracellular magnesium and quinidine. J Cardiovasc Pharmacol 33:181–185. https://doi.org/10.1097/00005344-199902000-00002

Podrid PJ, Myerburg RJ (2005) Epidemiology and stratification of risk for sudden cardiac death. Clin Cardiol 28:13-11. https://doi.org/10.1002/ccd.20512.0490281303

Pohjola-Sintonen S, Viitasalo M, Toivonen L, Neuvonen P (1993) Torsades de pointes after terfenadine-itraconazole interaction. BMJ 306:186. https://doi.org/10.1136/bmj.306.6871.186

Rajput SK, Singh JN, Sharma SS (2010) Evaluation of terfenadine and ketonazole-induced QT prolongation in conscious telemetry guinea pigs. Pharmacol Rep 62:683–688. https://doi.org/10.1016/j.pr.2010.07.0325-X

Rierzio I, Centini F, Neri M, Rossi G, Spanouudaki E, Turrillazzi E, Finieschi V (2009) Brugada-like EKG pattern and myocardial effects in a chronic propofol abuser. Clin Toxicol (Phila) 47:358–363. https://doi.org/10.1080/1556365902887842

Roden DM (2004) Drug-induced prolongation of the QT interval. N Engl J Med 350:1013–1022. https://doi.org/10.1056/NEJMra032426
consequences for in silico proarrhythmic risk prediction. Mol Pharmacol 90:1–11. https://doi.org/10.1124/mol.115.103127

Windley MJ, Lee W, Vandenberg JI, Hill AP (2018) The temperature dependence of kinetics associated with drug block of hERG channels Is compound-specific and an important factor for proarrhythmic risk prediction. Mol Pharmacol 94:760–769. https://doi.org/10.1124/mol.117.111534

Yang T, Snyder DS, Roden DM (1997) Rapid inactivation determines the rectification and [K+]o dependence of the rapid component of the delayed rectifier K+ current in cardiac cells. Circ Res 80:782–789. https://doi.org/10.1161/01.RES.80.6.782

Yang BF, Xu DH, Xu CQ, Li Z, Du ZM, Wang HZ, Dong DL (2004) Inactivation gating determines drug potency: a common mechanism for drug blockade of HERG channels. Acta Pharmacol Sin 25:554–560

Yao JA, Du X, Lu D, Baker RL, Daharsh E, Atterson P (2005) Estimation of potency of HERG channel blockers: impact of voltage protocol and temperature. J Pharmacol Toxicol Methods 52:146–153. https://doi.org/10.1016/j.vascn.2005.04.008

Yenigun EC, Aybak C, Turgut D, Aydin MZ, Dede F (2016) Effect of metabolic acidosis on QT intervals in patients with chronic kidney disease. Int J Artif Organs 39:272–276. https://doi.org/10.5301/iaro.5000509

Yu H, Zhang L, Liu J, Liu Y, Kowey PR, Zhang Y, Chen Y, Wei Y, Gao L, Li H, Du J, Xia Y (2017) Acquired long QT syndrome in hospitalized patients. Heart Rhythm 14:974–978. https://doi.org/10.1016/j.hrthm.2017.03.014

Zequn Z, Yujia W, Dingding Q, Jiangfang L (2021) Off-label use of chloroquine, hydroxychloroquine, azithromycin and lopinavir/ritonavir in COVID-19 risks prolonging the QT interval by targeting the hERG channel. Eur J Pharmacol 893:173813. https://doi.org/10.1016/ejphar.2020.173813

Zhang S, Zhou Z, Gong Q, Makielski JC, January CT (1999) Mechanism of block and identification of the verapamil binding domain to HERG potassium channels. Circ Res 84:989–998. https://doi.org/10.1161/01.RES.84.9.989

Zhi D, Feng PF, Sun J, Guo F, Zhang R, Zhao X, Li BX (2015) The enhancement of cardiac toxicity by concomitant administration of berberine and macrolides. Eur J Pharm Sci 76:149–155. https://doi.org/10.1016/j.ejps.2015.05.009

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395:1054–1062. https://doi.org/10.1016/S0140-6736(20)30566-3

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.